Shanghai Henlius Biotech Achieves First Patient Dosing in Phase I Trial for Fibrosis Treatment HLX6018
Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced the...
HKG: 2696
Shanghai Henlius Biotech Advances TIGIT-Targeting HLX53 to Phase II Clinical Trial for Hepatocellular Carcinoma
Shanghai Henlius Biotech Inc., (HKG: 2696), a biopharmaceutical company based in China, has received approval...
Shanghai Henlius Reports Phase III Success for HLX14 in Osteoporosis Treatment
Shanghai Henlius Biotech Inc. (HKG: 2696), based in China, has announced that its global, multi-center...
Henlius Biotech Posts 67.8% YOY Revenue Growth and First Annual Profit in 2023 Financials
Shanghai Henlius Biotech Inc., (HKG: 2696) has released its financial results for 2023, reporting revenues...
Shanghai Henlius Initiates Phase I Trial for HLX42, an Innovative ADC Targeting EGFR
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first subject dosing in a Phase...
Henlius Biotech’s HER2 Targeting Biosimilar Secures Thai and Philippine Approvals
Shanghai Henlius Biotech Inc., (HKG: 2696) a leading China-based biotech firm, has announced that its...
Henlius Biotech Forecasts First-Ever Profit in 2023 Driven by Sales Growth and Efficient Management
Shanghai Henlius Biotech Inc., (HKG: 2696), a China-based biopharmaceutical company, has released a positive profit...
MindRank Ltd Partners with Henlius Biotech to Pioneer AI-Powered Drug Therapies
MindRank Ltd, a China-based frontier in AI-enabled drug development, has inked a strategic partnership with...
Henlius Biotech Ships First International Batch of HanSiZhuang for Cancer Treatment to Indonesia
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biotech company from China, has announced the...
Henlius Biotech Secures Exclusive Rights to Sermonix’s Lasofoxifene for Breast Cancer Treatment in China
Shanghai Henlius Biotech Inc. (HKG: 2696) has entered into a partnership and licensing agreement with...
Medilink Therapeutics Secures Multi-Billion Dollar Deal with Roche for c-MET Targeting ADC
Medilink Therapeutics, a Suzhou-based biopharmaceutical company, has entered into a global collaboration and licensing agreement...
Shanghai Henlius Secures Indonesian Approval for HanSiZhuang in Small-Cell Lung Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696) has received market approval from the Indonesian Food and...
Fosun’s HLX42 Receives Fast-Track Designation from FDA for NSCLC Treatment
Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196; SHA: 600196) has announced that its antibody-drug conjugate...
AstraZeneca Advances to Phase III with PD-1xTIGIT BsAb for Biliary Tract Cancer
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical company, is set to initiate a Phase III...
Zhiyi Biotechnology and Henlius Biotech Partner to Develop Novel Drug Products and Platforms
Guangzhou-based Zhiyi Biotechnology has entered into a strategic partnership with Shanghai Henlius Biotech Inc. (HKG:...
Shanghai Henlius Biotech Submits Another Application for Serplulimab in China
Shanghai Henlius Biotech Inc., (HKG: 2696) has announced a new market filing for its anti-programmed...
Shanghai Henlius Partners with China Resource Medicine to Enhance Product Accessibility
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced a strategic partnership with China Resource Medicine...
Henlius Biotech Gets FDA Clearance for Clinical Study of PD-L1 Targeting ADC HLX43
Shanghai Henlius Biotech Inc. (HKG: 2696), a Chinese biopharmaceutical company, has received approval from the...
Fosun Pharmaceutical Gets FDA Green Light for HLX42 ADC Clinical Study
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has received approval from the US...
Shanghai Henlius Biotech Reports 84.0% YOY Revenue Growth in Q3 2023 Financials
Shanghai Henlius Biotech Inc., (HKG: 2696) a prominent player in the biopharmaceutical industry, has published...